Competitive exclusion of enteropathogens from human intestinal mucus by Bifidobacterium strains with acquired resistance to bilea preliminary study
First, the specific pathogenic or protective microbial species, microbial-derived metabolites, and mimic antigens relevant to different NIU subtypes remain to be identified
A 0.3 mL syringe works best for doses under 30 units, a 0.5 mL syringe handles doses up to 50 units, and a 1.0 mL syringe covers larger volumes
Where indicated, HFF-1-containing media were also incubated with a different treatment of either 10 or 30 mM GSH, or 4 g/mL amikacin alone, or a combination of 10 mM GSH + 4 g/mL amikacin, either in the presence or absence of bacteria
Concentration-wise, most serums land in the 1-2% range